<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407792</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Clinical Evaluation of Acute Exacerbation of Interstitial Lung Disease in a Single Tertiary Center: Perspectives before and after the Coronavirus Disease 2019 Pandemic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195733</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> Acute exacerbation (AE) of interstitial lung disease (ILD) is a major challenge. This study aimed to retrospectively investigate occurrences of AEs in patients with ILDs, including idiopathic pulmonary fibrosis (IPF), non-IPF (iNSIP: idiopathic nonspecific interstitial pneumonia), and connective tissue disease (CTD)-associated ILDs (CTD-ILDs), at a single tertiary center before and after the coronavirus disease 2019 (COVID-19) pandemic. The study aimed to clarify the seasonal and regional trends of AEs of ILDs, assess the roles of viral and bacterial infections, and identify key prognostic factors for patient outcomes. <b>Methods:</b> We conducted a retrospective review of hospitalized adult patients with AEs of ILDs from January 2019 to February 2024. <b>Results:</b> A total of 93 patients were enrolled: IPF (<i>n</i> = 42), iNSIP (<i>n</i> = 37), and CTD-ILDs (<i>n</i> = 14). The median age was 80 years (interquartile range: 74.0-86.0 years), with males comprising 64.5% (<i>n</i> = 60). AEs of ILDs predominantly occurred in winter and were particularly notable after summer 2023, coinciding with the lifting of COVID-19-related travel restrictions in Japan. Patient referrals from different areas (Northern Tama, East and/or Southern Tama, and other Tokyo metropolitan areas) were evenly distributed throughout the study period. Viral infections were detected in only two patients (SARS-CoV-2), and bacterial infections included methicillin-resistant <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>. The Cox regression analysis identified serum lactate dehydrogenase levels ≥350 IU/L and tachypnea (respiratory rate ≥ 30 breaths per min) on admission as prognostic factors for mortality, with a hazard ratio [HR] of 2.783 (95% confidence interval [CI]: 1.480-5.235, <i>p</i> = 0.001) and an HR of 3.332 (95% CI: 1.710-6.492, <i>p</i> &lt; 0.001), respectively. <b>Conclusions:</b> AEs of ILDs predominantly occur in winter, and viral and bacterial infections are infrequently detected. Elevated serum LDH levels and tachypnea are crucial prognostic markers for mortality. This study highlights the seasonal trend in the AE of ILD and emphasizes the importance of specific prognostic indicators in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraya</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0502-8128</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Sho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doi</LastName><ForeName>Kazuyuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akizawa</LastName><ForeName>Takatora</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Narishige</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurokawa</LastName><ForeName>Nozomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Fumi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunokawa</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aso</LastName><ForeName>Jumpei</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2721-4175</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamoto</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sada</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Kojiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamoto</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7140-6273</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takata</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Haruyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Tokyo 181-8611, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute exacerbation of interstitial pneumonia</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">prognostic factor</Keyword><Keyword MajorTopicYN="N">seasonal predilection</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407792</ArticleId><ArticleId IdType="pmc">PMC11477405</ArticleId><ArticleId IdType="doi">10.3390/jcm13195733</ArticleId><ArticleId IdType="pii">jcm13195733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jeganathan N., Sathananthan M. The prevalence and burden of interstitial lung diseases in the USA. ERJ Open Res. 2022;8:00630-2021. doi: 10.1183/23120541.00630-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00630-2021</ArticleId><ArticleId IdType="pmc">PMC8819246</ArticleId><ArticleId IdType="pubmed">35141319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondoh Y., Suda T., Hongo Y., Yoshida M., Hiroi S., Iwasaki K., Takeshima T., Homma S. Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir. Res. 2022;23:24. doi: 10.1186/s12931-022-01938-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-01938-6</ArticleId><ArticleId IdType="pmc">PMC8822670</ArticleId><ArticleId IdType="pubmed">35135550</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard H.R., Moore B.B., Flaherty K.R., Brown K.K., Kaner R.J., King T.E., Jr., Lasky J.A., Loyd J.E., Noth I., Olman M.A., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007;176:636–643. doi: 10.1164/rccm.200703-463PP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200703-463PP</ArticleId><ArticleId IdType="pmc">PMC2094133</ArticleId><ArticleId IdType="pubmed">17585107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y.W., Johnson J.E., Browning P.J., Cruz-Gervis R.A., Davis A., Graham B.S., Brigham K.L., Oates J.A., Jr., Loyd J.E., Stecenko A.A. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Microbiol. 2003;41:2633–2640. doi: 10.1128/JCM.41.6.2633-2640.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.41.6.2633-2640.2003</ArticleId><ArticleId IdType="pmc">PMC156536</ArticleId><ArticleId IdType="pubmed">12791891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushiki A., Yamazaki Y., Hama M., Yasuo M., Hanaoka M., Kubo K. Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. Respir. Investig. 2014;52:65–70. doi: 10.1016/j.resinv.2013.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2013.07.005</ArticleId><ArticleId IdType="pmc">PMC7104067</ArticleId><ArticleId IdType="pubmed">24388373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton S.C., Kim D.S., Kondoh Y., Chen E., Lee J.S., Song J.W., Huh J.W., Taniguchi H., Chiu C., Boushey H., et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 2011;183:1698–1702. doi: 10.1164/rccm.201010-1752OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201010-1752OC</ArticleId><ArticleId IdType="pmc">PMC3136996</ArticleId><ArticleId IdType="pubmed">21471095</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraya T., Kimura H., Kurai D., Tamura M., Ogawa Y., Mikura S., Sada M., Oda M., Watanabe T., Ohkuma K., et al. Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases. Respir. Med. 2018;136:88–92. doi: 10.1016/j.rmed.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2018.02.003</ArticleId><ArticleId IdType="pmc">PMC7125637</ArticleId><ArticleId IdType="pubmed">29501253</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraya T., Kimura H., Kurai D., Ishii H., Takizawa H. The molecular epidemiology of respiratory viruses associated with asthma attacks. A single-center observational study in Japan. Medicine. 2017;96:e8204. doi: 10.1097/MD.0000000000008204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000008204</ArticleId><ArticleId IdType="pmc">PMC5662372</ArticleId><ArticleId IdType="pubmed">29049206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamano J., Tokuda Y. Changes in vital signs as predictors of bacterial infection in home care: A multi-center prospective cohort study. Postgrad. Med. 2017;129:283–287. doi: 10.1080/00325481.2017.1251819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2017.1251819</ArticleId><ArticleId IdType="pubmed">27766928</ArticleId></ArticleIdList></Reference><Reference><Citation>The Ministry of Health LaWoJ  Idiopathic Interstitial Pneumonia; 2024.  [(accessed on 18 September 2024)].  Available online:  https://www.nanbyou.or.jp/entry/302.</Citation></Reference><Reference><Citation>Mostafaei S., Sayad B., Azar M.E.F., Doroudian M., Hadifar S., Behrouzi A., Riahi P., Hussen B.M., Bayat B., Nahand J.S., et al. The role of viral and bacterial infections in the pathogenesis of IPF: A systematic review and meta-analysis. Respir. Res. 2021;22:53. doi: 10.1186/s12931-021-01650-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01650-x</ArticleId><ArticleId IdType="pmc">PMC7880524</ArticleId><ArticleId IdType="pubmed">33579274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng G., Chen P., Wei Y., Yue H., Chu J., Zhao J., Wang Y., Zhang W., Zhang H.L. Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Chest. 2020;157:1175–1187. doi: 10.1016/j.chest.2019.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.10.032</ArticleId><ArticleId IdType="pmc">PMC7214095</ArticleId><ArticleId IdType="pubmed">31730835</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard H.R., Yow E., Richeldi L., Anstrom K.J., Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir. Res. 2013;14:73. doi: 10.1186/1465-9921-14-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-14-73</ArticleId><ArticleId IdType="pmc">PMC3729659</ArticleId><ArticleId IdType="pubmed">23848435</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Blancal V., Freynet O., Nunes H., Bouvry D., Naggara N., Brillet P.Y., Denis D., Cohen Y., Vincent F., Valeyre D., et al. Acute exacerbation of idiopathic pulmonary fibrosis: Outcome and prognostic factors. Respiration. 2012;83:28–35. doi: 10.1159/000329891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000329891</ArticleId><ArticleId IdType="pubmed">21860222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazoe M., Tomioka H. Acute exacerbation of idiopathic pulmonary fibrosis: A 10-year single-centre retrospective study. BMJ Open Respir. Res. 2018;5:e000342. doi: 10.1136/bmjresp-2018-000342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2018-000342</ArticleId><ArticleId IdType="pmc">PMC6203000</ArticleId><ArticleId IdType="pubmed">30397488</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindo Y., Ito R., Kobayashi D., Ando M., Ichikawa M., Goto Y., Fukui Y., Iwaki M., Okumura J., Yamaguchi I., et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: An observational cohort study. Lancet Infect. Dis. 2015;15:1055–1065. doi: 10.1016/S1473-3099(15)00151-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00151-6</ArticleId><ArticleId IdType="pubmed">26145194</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Beheidy R., Domouky A.M., Zidan H., Amer Y.A. Serum KL-6 as predictive and prognostic marker of interstitial lung disease in childhood connective tissue diseases: A pilot study. Reumatismo. 2021;73:147–155. doi: 10.4081/reumatismo.2021.1399.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2021.1399</ArticleId><ArticleId IdType="pubmed">34814656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng P., Zheng X., Takehiro H., Cheng Z.J., Wang J., Xue M., Lin Q., Huang Z., Huang H., Liao C., et al. The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease. J. Transl. Int. Med. 2021;9:212–222. doi: 10.2478/jtim-2021-0040.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/jtim-2021-0040</ArticleId><ArticleId IdType="pmc">PMC8629416</ArticleId><ArticleId IdType="pubmed">34900632</ArticleId></ArticleIdList></Reference><Reference><Citation>Groseanu L., Nita C. A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Diagnostics. 2024;14:1890. doi: 10.3390/diagnostics14171890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics14171890</ArticleId><ArticleId IdType="pmc">PMC11394114</ArticleId><ArticleId IdType="pubmed">39272673</ArticleId></ArticleIdList></Reference><Reference><Citation>Gono T., Kawaguchi Y., Satoh T., Kuwana M., Katsumata Y., Takagi K., Masuda I., Tochimoto A., Baba S., Okamoto Y., et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–1719. doi: 10.1093/rheumatology/keq149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keq149</ArticleId><ArticleId IdType="pubmed">20498012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Guo Q., Chi J., Wu H., Bao C. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin. Rheumatol. 2015;34:707–714. doi: 10.1007/s10067-015-2866-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-2866-5</ArticleId><ArticleId IdType="pubmed">25609178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishaba T., Tamaki H., Shimaoka Y., Fukuyama H., Yamashiro S. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung. 2014;192:141–149. doi: 10.1007/s00408-013-9530-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-013-9530-0</ArticleId><ArticleId IdType="pubmed">24221341</ArticleId></ArticleIdList></Reference><Reference><Citation>Murohashi K., Hara Y., Saigusa Y., Kobayashi N., Sato T., Yamamoto M., Kudo M., Kaneko T. Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. J. Thorac. Dis. 2019;11:2448–2457. doi: 10.21037/jtd.2019.05.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2019.05.46</ArticleId><ArticleId IdType="pmc">PMC6626781</ArticleId><ArticleId IdType="pubmed">31372282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb M., Bondue B., Pesci A., Miyazaki Y., Song J.W., Bhatt N.Y., Huggins J.T., Oldham J.M., Padilla M.L., Roman J., et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018;27:180071. doi: 10.1183/16000617.0071-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0071-2018</ArticleId><ArticleId IdType="pmc">PMC9488799</ArticleId><ArticleId IdType="pubmed">30578331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>